Research progress on immunotherapy for nasopharyngeal carcinoma

VernacularTitle:鼻咽癌免疫治疗进展
Author: Fengge ZHOU ; Junlin YI
From: Chinese Journal of Radiation Oncology 2021;30(4):407-412
CountryChina
Language:Chinese
Abstract: Nasopharyngeal carcinoma (NPC) is a malignant carcinoma that is closely associated with Epstein Barr virus (EBV) infection. After the comprehensive treatment based on modern intensity-modulated radiation therapy, the oncological outcomes can be further improved. The main target of treatment is to increase the efficacy of patients with high risk and recurrent/metastatic (R/M) NPC. Recently, continuous progress has been made in the application of immunotherapy in the field of cancer treatment. Based on the accumulated knowledge on EBV antigen and immune checkpoint inhibitors, significant progress has been made in use of immunotherapy in treating R/M-NPC. Immunotherapy combined with radiotherapy or chemoradiotherapy will become the hot spot in the clinical management of patients with newly-diagnosed high-risk NPC.